XML 68 R58.htm IDEA: XBRL DOCUMENT
v3.21.2

Commitments and Contingencies - Contingencies - Additional Information (Detail) € in Millions |  |  |  |  |  | 1 Months Ended | 6 Months Ended | 12 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 21, 2021 USD ($) | Nov. 20, 2020 EUR (€) | Oct. 21, 2019 USD ($) | Aug. 21, 2017 USD ($) | Jul. 15, 2015 USD ($) | May 31, 2019 USD ($) | Aug. 31, 2012 USD ($) | Dec. 31, 2010 USD ($) | Aug. 31, 2008 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2014 USD ($) | Jul. 08, 2021 USD ($) | Sep. 01, 2020 USD ($) | Jan. 31, 2009 USD ($) | Jul. 31, 2008 USD ($) | Feb. 28, 2005 USD ($)
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damages assessment |  |  |  |  |  |  |  |  |  | $ 235,500,000 |  |  |  |  |  |  |
Annual sales at the time of settlement |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 700,000,000 | $ 350,000,000 |  |
Annual sales of Effexor |  |  |  | $ 2,600,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Lamictal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,300,000,000 | $ 950,000,000
Annual sales of Aggrenox |  |  |  |  | $ 1,100,000 |  |  |  | $ 416,000,000 |  |  |  |  |  |  |  |
Annual sales of Actos |  |  |  |  |  |  | $ 2,800,000,000 | $ 3,700,000,000 |  |  |  |  |  |  |  |  |
Annual sales of Acto plus |  |  |  |  |  |  | $ 430,000,000 | $ 500,000,000 |  |  |  |  |  |  |  |  |
Annual Sales Of Sensipar |  |  |  |  |  |  |  |  |  |  | $ 1,400,000,000 |  |  |  |  |  |
Annual Sales Of Copaxone |  |  |  |  |  |  |  |  |  |  |  | $ 380,000,000 |  |  |  |  |
Fines Imposed In Period | € |  | € 60.5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, claims dismissed, value |  |  |  |  |  |  |  |  |  | 925,000 |  |  |  |  |  |  |
Accrual for environmental loss contingencies |  |  |  |  |  |  |  |  |  | 300,000 |  |  |  |  |  |  |
Loss contingencies on environmental laws, penalty |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,400,000 |  |  |  |
Opioid Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount |  |  | $ 25,000,000 |  |  | $ 85,000,000 |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount awarded distribution period |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount awarded cash amount |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nationwide Settlement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount |  |  | $ 23,000,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount awarded distribution period |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount awarded cash amount |  |  | $ 250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount awarded cash amount distribution period |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nationwide Settlement [Member] | Subsequent Event [Member] | Four Other Defendants Other Than Teva [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency payment | $ 26,000,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount awarded distribution period | 18 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  | 200,000,000 |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] | United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  | 150,000,000 |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] | Europe [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |
AndroGel Rate at 1% [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales at the time of settlement |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 140,000,000 |  |

X
- Definition Annual sales at time of settlement. + References No definition available. + Details
Name: | teva_AnnualSalesAtTimeOfSettlement
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Annual sales of Acto plus. + References No definition available. + Details
Name: | teva_AnnualSalesOfActoplus
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Actos. + References No definition available. + Details
Name: | teva_AnnualSalesOfActos
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Aggrenox. + References No definition available. + Details
Name: | teva_AnnualSalesOfAggrenox
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual Sales Of Copaxone. + References No definition available. + Details
Name: | teva_AnnualSalesOfCopaxone
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of effexor. + References No definition available. + Details
Name: | teva_AnnualSalesOfEffexor
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Lamictal. + References No definition available. + Details
Name: | teva_AnnualSalesOfLamictal
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents Annual Sales Of Sensipar. + References No definition available. + Details
Name: | teva_AnnualSalesOfSensipar
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Commitment And Contingencies [Line Items] + References No definition available. + Details
Name: | teva_CommitmentAndContingenciesLineItems
Namespace Prefix: | teva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Damages assessment. + References No definition available. + Details
Name: | teva_DamagesAssessment
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Litigation settlement amount awarded cash amount. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountAwardedCashAmount
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Litigation settlement amount awarded cash amount distribution period. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod
Namespace Prefix: | teva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Litigation settlement amount awarded distribution period. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountAwardedDistributionPeriod
Namespace Prefix: | teva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss contingencies on environmental laws, penalty. + References No definition available. + Details
Name: | teva_LossContingenciesOnEnvironmentalLawsPenalty
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loss contingency, claims dismissed, value. + References No definition available. + Details
Name: | teva_LossContingencyClaimsDismissedValue
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Total costs accrued as of the balance sheet date for environmental loss contingencies. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 25 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6395460&loc=d3e13647-108346 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 410 -SubTopic 30 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859 + Details
Name: | us-gaap_AccrualForEnvironmentalLossContingencies
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of damages paid to the plaintiff in the legal matter. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesPaidValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyLossInPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_LitigationCaseAxis=teva_OpioidLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=teva_NationwideSettlementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | teva_DefendantsAxis=teva_FourOtherDefendantsOtherThanTevaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |